nnpNeurology, Neuropsychiatry, PsychosomaticsНеврология, нейропсихиатрия, психосоматика2074-27112310-1342"IMA-Press", LLC10.14412/2074-2711-2022-6-110-114nnp-1929Research ArticleREVIEWSОБЗОРЫMild cognitive impairment treatment issuesВопросы терапии умеренных когнитивных нарушенийhttps://orcid.org/0000-0001-6951-2205ЩепанкевичЛ. А.ShсhepankevichL. A.

Лариса Александровна Щепанкевич

630091, Новосибирск, Красный проспект, 52630117, Новосибирск, ул. Тимакова, 2630087, Новосибирск, ул. Немировича-Данченко, 130

Larisa Alexandrovna Shchepankevich

630091, Novosibirsk, Krasny Prosp., 52630117, Novosibirsk, Timakova St., 2630087, Novosibirsk, Nemirovich-Danchenko St., 130

shepankevich@rambler.ruhttps://orcid.org/0000-0001-8477-7746ГрибачеваИ. А.GribachevaI. A.

630091, Новосибирск, Красный проспект, 52

630091, Novosibirsk, Krasny Prosp., 52

https://orcid.org/0000-0003-2543-422XПоповаТ. Ф.PopovaT. F.

630091, Новосибирск, Красный проспект, 52

630091, Novosibirsk, Krasny Prosp., 52

https://orcid.org/0000-0002-6538-6069ТанееваЕ. В.TaneevaE. V.

630087, Новосибирск, ул. Немировича-Данченко, 130

630087, Novosibirsk, Nemirovich-Danchenko St., 130

https://orcid.org/0000-0002-4141-9161РерихК. В.RoerichK. V.

630087, Новосибирск, ул. Немировича-Данченко, 130

630087, Novosibirsk, Nemirovich-Danchenko St., 130

https://orcid.org/0000-0003-3839-655XПетроваЕ. В.PetrovaE. V.

630091, Новосибирск, Красный проспект, 52

630091, Novosibirsk, Krasny Prosp., 52

https://orcid.org/0000-0001-5141-3292ЩепанкевичМ. С.ShchepankevichM. S.

630091, Новосибирск, Красный проспект, 52

630091, Novosibirsk, Krasny Prosp., 52

Кафедра неврологии ФГБОУ ВО «Новосибирский государственный медицинский университет» Минздрава России; ФГБНУ «Федеральный исследовательский центр фундаментальной и трансляционной медицины»; ГБУЗ Новосибирской области «Государственная Новосибирская областная клиническая больница»РоссияDepartment of Neurology, Novosibirsk State Medical University, Ministry of Health of Russia; Federal Research Center for Fundamental and Translational Medicine; State Novosibirsk Regional Clinical HospitalRussian FederationКафедра неврологии ФГБОУ ВО «Новосибирский государственный медицинский университет» Минздрава РоссииРоссияDepartment of Neurology, Novosibirsk State Medical University, Ministry of Health of RussiaRussian FederationГБУЗ Новосибирской области «Государственная Новосибирская областная клиническая больница»РоссияState Novosibirsk Regional Clinical HospitalRussian Federation202219122022146110114Copyright © Shсhepankevich L.A., Gribacheva I.A., Popova T.F., Taneeva E.V., Roerich K.V., Petrova E.V., Shchepankevich M.S., 20222022Щепанкевич Л.А., Грибачева И.А., Попова Т.Ф., Танеева Е.В., Рерих К.В., Петрова Е.В., Щепанкевич М.С.Shсhepankevich L.A., Gribacheva I.A., Popova T.F., Taneeva E.V., Roerich K.V., Petrova E.V., Shchepankevich M.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://nnp.ima-press.net/nnp/article/view/1929

The development of dementia is preceded by mild cognitive impairment (MCI), the treatment of which can slow down the transformation of MCI into dementia. The article discusses drug and non-drug therapies for MCI. Multiple pharmacological effects of citicoline on cognitive functions of patient’s with MCI and mild vascular dementia or Alzheimer's disease are analyzed. The need for long-term therapy with citicoline is actualized, increasing adherence to therapy by prescribing a convenient form of the drug Noocil (240 ml bottle, liquid form of citicoline for oral administration).

Развитию деменции предшествуют умеренные когнитивные нарушения (УКН), лечение которых может замедлить трансформацию УКН в деменцию. В статье обсуждаются лекарственные и нелекарственные методы терапии УКН. Проводится анализ множественных фармакологических эффектов цитиколина по влиянию на когнитивные функции у пациентов с УКН и легкой деменцией сосудистого генеза или при болезни Альцгеймера. Актуализируется необходимость длительной терапии цитиколином, повышение приверженности терапии путем назначения удобной формы выпуска препарата Нооцил (флакон 240 мл, жидкая форма цитиколина для приема внутрь).

когнитивные нарушениядеменцияцитиколиннооциллечениеcognitive impairmentdementiaciticolinenoocyltreatmentСтатья спонсируется компанией «Озон Фарма».This article has been supported by Ozon Pharma.ReferencesMeijer E, Casanova M, Kim H, et al. Economic costs of dementia in 11 countries in Europe: Estimates from nationally representative cohorts of a panel study. Lancet Reg Health Eur. 2022 Jun 24;20:100445. doi:10.1016/j.lanepe.2022.100445Meijer E, Casanova M, Kim H, et al. Economic costs of dementia in 11 countries in Europe: Estimates from nationally representative cohorts of a panel study. Lancet Reg Health Eur. 2022 Jun 24;20:100445. doi:10.1016/j.lanepe.2022.100445WHO, World Health Organization. Methodology for Producing Global Dementia Cost Estimates. 2021. Global status report on the public health response to dementia, Web Annex. Geneva: World Health Organization; 2021.WHO, World Health Organization. Methodology for Producing Global Dementia Cost Estimates. 2021. Global status report on the public health response to dementia, Web Annex. Geneva: World Health Organization; 2021.Kua EH, Ho E, Tan HH, et al. The natural history of dementia. Psychogeriatrics. 2014 Sep;14(3):196-201. doi:10.1111/psyg.12053Kua EH, Ho E, Tan HH, et al. The natural history of dementia. Psychogeriatrics. 2014 Sep;14(3):196-201. doi:10.1111/psyg.12053Overton M, Pihlsgаrd M, Elmstahl S. Prevalence and Incidence of Mild Cognitive Impairment across Subtypes, Age, and Sex. Dement Geriatr Cogn Disord. 2019;47(4-6):219-32. doi:10.1159/000499763. Epub 2019 Jul 16.Overton M, Pihlsgаrd M, Elmstahl S. Prevalence and Incidence of Mild Cognitive Impairment across Subtypes, Age, and Sex. Dement Geriatr Cogn Disord. 2019;47(4-6):219-32. doi:10.1159/000499763. Epub 2019 Jul 16.Han F, Luo C, Lv D, et al. Risk Factors Affecting Cognitive Impairment of the Elderly Aged 65 and Over: A Cross-Sectional Study. Front Aging Neurosci. 2022 Jun16;14:903794. doi:10.3389/fnagi.2022.903794Han F, Luo C, Lv D, et al. Risk Factors Affecting Cognitive Impairment of the Elderly Aged 65 and Over: A Cross-Sectional Study. Front Aging Neurosci. 2022 Jun16;14:903794. doi:10.3389/fnagi.2022.903794Patnode CD, Perdue LA, Rossom RC, et al. Screening for Cognitive Impairment in Older Adults: An Evidence Update for the U.S. Preventive Services Task Force [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2020 Feb. Report No.: 19-05257-EF-1.Patnode CD, Perdue LA, Rossom RC, et al. Screening for Cognitive Impairment in Older Adults: An Evidence Update for the U.S. Preventive Services Task Force [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2020 Feb. Report No.: 19-05257-EF-1.Wardlaw JM, Debette S, Jokinen H, et al. ESO Guideline on covert cerebral small vessel disease. Eur Stroke J. 2021 Jun;6(2):CXICLXII. doi:10.1177/23969873211012132. Epub 2021 May 11.Wardlaw JM, Debette S, Jokinen H, et al. ESO Guideline on covert cerebral small vessel disease. Eur Stroke J. 2021 Jun;6(2):CXICLXII. doi:10.1177/23969873211012132. Epub 2021 May 11.Парфенов ВА. Сосудистые когнитивные нарушения и хроническая ишемия головного мозга (дисциркуляторная энцефалопатия). Неврология, нейропсихиатрия, психосоматика. 2019;11(3S):61-7. doi:10.14412/2074-2711-2019-3S-61-67Parfenov VA. Vascular cognitive disorders and chronic cerebral ischemia (dyscirculatory encephalopathy). Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatic. 2019;11(3S):61-7. doi:10.14412/2074-2711-2019-3S-61-67 (In Russ.).Громова ОА, Торшин ИЮ, Гришина ТР и др. Молекулярные и клинические аспекты действия цитидиндифосфохолина на когнитивные функции. Журнал неврологии и психиатрии им. С.С. Корсакова. 2021;121(5):8897. doi:10.17116/jnevro202112105188Gromova OA, Torshin IYu, Grishina TR, et al. Molecular and clinical aspects of the effect of cytidyndiphosphocholine on cognitive functions. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2021;121(5):8897. doi:10.17116/jnevro202112105188 (In Russ.).Singh B, Parsaik AK, Mielke MM, et al. Association of mediterranean diet with mild cognitive impairment and Alzheimer's disease: a systematic review and meta-analysis. J Alzheimers Dis. 2014;39(2):271-82. doi:10.3233/JAD-130830Singh B, Parsaik AK, Mielke MM, et al. Association of mediterranean diet with mild cognitive impairment and Alzheimer's disease: a systematic review and meta-analysis. J Alzheimers Dis. 2014;39(2):271-82. doi:10.3233/JAD-130830Ertel KA, Glymour MM, Berkman LF. Effects of social integration on preserving memory function in a nationally representative US elderly population. Am J Public Health. 2008 Jul;98(7):1215-20. doi:10.2105/AJPH.2007.113654. Epub 2008 May 29.Ertel KA, Glymour MM, Berkman LF. Effects of social integration on preserving memory function in a nationally representative US elderly population. Am J Public Health. 2008 Jul;98(7):1215-20. doi:10.2105/AJPH.2007.113654. Epub 2008 May 29.Russ TC, Morling JR. Cholinesterase inhibitors for mild cognitive impairment. Cochrane Database Syst Rev. 2012 Sep 12;2012(9):CD009132. doi:10.1002/14651858.CD009132.pub2Russ TC, Morling JR. Cholinesterase inhibitors for mild cognitive impairment. Cochrane Database Syst Rev. 2012 Sep 12;2012(9):CD009132. doi:10.1002/14651858.CD009132.pub2Smith E. Vascular Cognitive Impairment. Continuum (Minneap Minn). 2016 Apr;22(2 Dementia):490-509. doi:10.1212/CON.0000000000000304Smith E. Vascular Cognitive Impairment. Continuum (Minneap Minn). 2016 Apr;22(2 Dementia):490-509. doi:10.1212/CON.0000000000000304Petersen RC, Lopez O, Armstrong MJ, et al. Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018 Jan 16;90(3):126-35. doi:10.1212/WNL.0000000000004826. Epub 2017 Dec 27.Petersen RC, Lopez O, Armstrong MJ, et al. Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018 Jan 16;90(3):126-35. doi:10.1212/WNL.0000000000004826. Epub 2017 Dec 27.Herskovits AZ, Guarente L. SIRT1 in neurodevelopment and brain senescence. Neuron. 2014 Feb 5;81(3):471-83. doi:10.1016/j.neuron.2014.01.028Herskovits AZ, Guarente L. SIRT1 in neurodevelopment and brain senescence. Neuron. 2014 Feb 5;81(3):471-83. doi:10.1016/j.neuron.2014.01.028Xu J, Jackson CW, Khoury N, et al. Brain SIRT1 Mediates Metabolic Homeostasis and Neuroprotection. Front Endocrinol. 2018;9:702. doi:10.3389/fendo.2018.00702Xu J, Jackson CW, Khoury N, et al. Brain SIRT1 Mediates Metabolic Homeostasis and Neuroprotection. Front Endocrinol. 2018;9:702. doi:10.3389/fendo.2018.00702Bonda DJ, Lee H-G, Camins A, et al. The sirtuin pathway in ageing and Alzheimer disease: Mechanistic and therapeutic considerations. Lancet Neurol. 2011;10:275-9. doi:10.1016/S1474-4422(11)70013-8Bonda DJ, Lee H-G, Camins A, et al. The sirtuin pathway in ageing and Alzheimer disease: Mechanistic and therapeutic considerations. Lancet Neurol. 2011;10:275-9. doi:10.1016/S1474-4422(11)70013-8Donmez G, Arun A, Chung C-Y, et al. SIRT1 protects against α-synuclein aggregation by activating molecular chaperones. J Neurosci. 2012;32:124-32. doi:10.1523/JNEUROSCI.3442-11.2012Donmez G, Arun A, Chung C-Y, et al. SIRT1 protects against α-synuclein aggregation by activating molecular chaperones. J Neurosci. 2012;32:124-32. doi:10.1523/JNEUROSCI.3442-11.2012Secades JJ. Citicoline: Pharmacological and clinical review, 2016 update. Rev Neurol. 2016 Dec 23;63(S03):S1-S73.Secades JJ. Citicoline: Pharmacological and clinical review, 2016 update. Rev Neurol. 2016 Dec 23;63(S03):S1-S73.Synoradzki K, Grieb P. Citicoline: A Superior Form of Choline? Nutrients. 2019;11:1569. doi:10.3390/nu11071569Synoradzki K, Grieb P. Citicoline: A Superior Form of Choline? Nutrients. 2019;11:1569. doi:10.3390/nu11071569Blusztajn JK, Slack BE, Mellott TJ. Neuroprotective Actions of Dietary Choline. Nutrients. 2017;9:815. doi:10.3390/nu9080815Blusztajn JK, Slack BE, Mellott TJ. Neuroprotective Actions of Dietary Choline. Nutrients. 2017;9:815. doi:10.3390/nu9080815Roohi-Azizi M, Torkaman-Boutorabi A, Akhondzadeh S, et al. Influence of citicoline on citalopram-induced antidepressant activity in depressive-like symptoms in male mice. Physiol Behav. 2018;195:151-7. doi:10.1016/j.physbeh.2018.08.002Roohi-Azizi M, Torkaman-Boutorabi A, Akhondzadeh S, et al. Influence of citicoline on citalopram-induced antidepressant activity in depressive-like symptoms in male mice. Physiol Behav. 2018;195:151-7. doi:10.1016/j.physbeh.2018.08.002Babb S, Wald L, Cohen B, et al. Chronic citicoline increases phosphodiesters in the brains of healthy older subjects: An in vivo phosphorus magnetic resonance spectroscopy study. Psychopharmacology. 2002;161:248-54.Babb S, Wald L, Cohen B, et al. Chronic citicoline increases phosphodiesters in the brains of healthy older subjects: An in vivo phosphorus magnetic resonance spectroscopy study. Psychopharmacology. 2002;161:248-54.Adibhatla RM, Hatcher JF. Citicoline decreases phospholipase A2 stimulation and hydroxyl radical generation in transient cerebral ischemia. J Neurosci Res. 2003;73:308-15. doi:10.1002/jnr.10672Adibhatla RM, Hatcher JF. Citicoline decreases phospholipase A2 stimulation and hydroxyl radical generation in transient cerebral ischemia. J Neurosci Res. 2003;73:308-15. doi:10.1002/jnr.10672Mosharrof AH, Petkov VD. Effects of citicholine and of the combination citicholine + piracetam on the memory (experiments on mice) Acta Physiol Pharm Bulg. 1990;16:25-31.Mosharrof AH, Petkov VD. Effects of citicholine and of the combination citicholine + piracetam on the memory (experiments on mice) Acta Physiol Pharm Bulg. 1990;16:25-31.Gareri P, Cotroneo AM, Castagna A, et al. Effectiveness and safety of citicoline in mild vascular cognitive impairment: The IDEALE study. Clin Interv Aging. 2013;8:131-7. doi:10.2147/CIA.S38420Gareri P, Cotroneo AM, Castagna A, et al. Effectiveness and safety of citicoline in mild vascular cognitive impairment: The IDEALE study. Clin Interv Aging. 2013;8:131-7. doi:10.2147/CIA.S38420Castagna A, Cotroneo AM, Ruotolo G, Gareri P. The CITIRIVAD Study: CITIcoline plus RIVAstigmine in Elderly Patients Affected with Dementia Study. Clin Drug Investig. 2016;36:1059-65. doi:10.1007/s40261-016-0454-3Castagna A, Cotroneo AM, Ruotolo G, Gareri P. The CITIRIVAD Study: CITIcoline plus RIVAstigmine in Elderly Patients Affected with Dementia Study. Clin Drug Investig. 2016;36:1059-65. doi:10.1007/s40261-016-0454-3Gareri P, Castagna A, Cotroneo AM, et al. The Citicholinage Study: Citicoline Plus Cholinesterase Inhibitors in Aged Patients Affected with Alzheimer’s Disease Study. J Alzheimer’s Dis. 2017;56:557-65. doi:10.3233/JAD-160808Gareri P, Castagna A, Cotroneo AM, et al. The Citicholinage Study: Citicoline Plus Cholinesterase Inhibitors in Aged Patients Affected with Alzheimer’s Disease Study. J Alzheimer’s Dis. 2017;56:557-65. doi:10.3233/JAD-160808Alvarez XA, Mouzo R, Pichel V, et al. Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer’s disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion. Methods Find Exp Clin Pharm. 1999;21:633-44.Alvarez XA, Mouzo R, Pichel V, et al. Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer’s disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion. Methods Find Exp Clin Pharm. 1999;21:633-44.Amenta F, Battineni G, Traini E, Pallotta G. Choline-containing phospholipids and treatment of adult-onset dementia disorders. In: Diagnosis and Management in Dementia. Academic Press; 2020. P. 477-93.Amenta F, Battineni G, Traini E, Pallotta G. Choline-containing phospholipids and treatment of adult-onset dementia disorders. In: Diagnosis and Management in Dementia. Academic Press; 2020. P. 477-93.

The authors declare that there are no conflicts of interest present.